Monopar Therapeutics Inc
MNPR41.280USD
+0.590+1.45%
交易中 （美東）報價延遲15分鐘
252.44M總市值
虧損本益比TTM
關於 Monopar Therapeutics Inc 公司
Monopar Therapeutics Inc. 是一家臨牀階段的生物製藥公司，專注於開發癌症患者的治療方法。該公司正在通過內部開發以及授權和收購處於臨牀前和臨牀開發階段的治療藥物來建立候選藥物渠道。該公司正在開發幾種化合物，包括 MNPR-101-Zr、MNPR-101-RIT、Camsirubicin 和 MNPR-202。MNPR-101-Zr 是一種臨牀階段的尿激酶纖溶酶原激活劑受體 (uPAR) 靶向放射診斷顯像劑。MNPR-101-RIT 是一種用於晚期癌症的臨牀前階段放射治療藥物。Camsirubicin 是阿黴素的類似物，旨在減少阿黴素產生的心臟毒性副作用，同時保留有效的抗癌活性。 MNPR-202 是卡馬西柔比星的早期類似物，旨在治療對阿黴素和卡馬西柔比星有耐藥性的癌症。
公司簡介
公司代碼MNPR
公司名稱Monopar Therapeutics Inc
上市日期Dec 19, 2019
CEODr. Chandler D. Robinson, M.D.
員工數量16
證券類型Ordinary Share
年結日Dec 19
公司地址1000 Skokie Blvd Ste 350
城市WILMETTE
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編60091-1146
電話18473880349
網址https://www.monopartx.com/
公司代碼MNPR
上市日期Dec 19, 2019
CEODr. Chandler D. Robinson, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
73.47K
--
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
6.17K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Mr. Vu Quan
Mr. Vu Quan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Dr. Patrice P. Rioux, M.D., Ph.D.
Dr. Patrice P. Rioux, M.D., Ph.D.
Acting Chief Medical Officer
Acting Chief Medical Officer
--
--
Mr. Andrew J. Cittadine
Mr. Andrew J. Cittadine
Chief Operating Officer
Chief Operating Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
73.47K
--
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
6.17K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月5日 週六
更新時間: 7月5日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Janus Henderson Investors
18.55%
Tactic Pharma LLC
13.45%
Gem Pharmaceuticals LLC
9.99%
Adage Capital Management, L.P.
9.80%
RA Capital Management, LP
8.36%
Other
39.85%
持股股東
持股股東
佔比
Janus Henderson Investors
18.55%
Tactic Pharma LLC
13.45%
Gem Pharmaceuticals LLC
9.99%
Adage Capital Management, L.P.
9.80%
RA Capital Management, LP
8.36%
Other
39.85%
股東類型
持股股東
佔比
Corporation
29.77%
Investment Advisor/Hedge Fund
20.22%
Hedge Fund
16.45%
Venture Capital
8.36%
Individual Investor
4.79%
Investment Advisor
1.81%
Research Firm
0.55%
Pension Fund
0.15%
Other
17.91%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
75
5.02M
82.10%
-394.73K
2025Q1
72
5.03M
83.96%
+455.96K
2024Q4
54
4.84M
79.28%
+1.76M
2024Q3
40
1.90M
50.69%
+25.14K
2024Q2
43
1.96M
52.51%
+123.52K
2024Q1
46
1.91M
52.92%
+136.66K
2023Q4
44
1.88M
67.20%
+125.61K
2023Q3
42
1.87M
67.45%
+153.91K
2023Q2
38
1.84M
66.75%
+138.58K
2023Q1
38
1.70M
67.19%
-3.29K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Janus Henderson Investors
1.13M
18.55%
+87.51K
+8.36%
Mar 31, 2025
Tactic Pharma LLC
822.25K
13.45%
-33.33K
-3.90%
Apr 04, 2025
Gem Pharmaceuticals LLC
611.08K
9.99%
--
--
Apr 04, 2025
Adage Capital Management, L.P.
599.20K
9.8%
--
--
Mar 31, 2025
RA Capital Management, LP
511.21K
8.36%
--
--
Mar 31, 2025
AstraZeneca PLC
387.33K
6.33%
+387.33K
--
Oct 23, 2024
Point72 Asset Management, L.P.
168.16K
2.75%
+268.00
+0.16%
Mar 31, 2025
Adar1 Capital Management LLC
100.77K
1.65%
-29.26K
-22.50%
Mar 31, 2025
Hendricks (Diane)
93.75K
1.53%
--
--
Apr 04, 2025
Robinson (Chandler D)
73.47K
1.2%
+7.48K
+11.33%
Jun 30, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
佔比0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.02%
ProShares UltraPro Russell2000
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
iShares Russell 2000 Growth ETF
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
iShares Russell 2000 ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
公告日期
類型
比率
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
